神经肌肉阻滞剂用于成人急性呼吸窘迫综合征:随机对照试验的荟萃分析
该荟萃分析纳入5项随机对照试验共551例成人ARDS患者,所有试验均基于保护性通气策略,患者氧合指数≤200 mm Hg且符合美欧共识会议或柏林定义。神经肌肉阻滞剂显著降低ICU死亡率(RR 0.73,95%CI 0.58–0.93,P=0.009)和21–28天死亡率(RR 0.63,95%CI 0.49–0.82,P=0.001)。48小时氧合改善(WMD 27.98,95%CI 7.45–48.51,P=0.008),但24小时氧合、48小时平台压及呼气末正压无显著差异。结论认为基于保护性通气策略的神经肌肉阻滞剂治疗可降低中重度ARDS患者死亡率。
要点
- 中重度ARDS成人(氧合指数≤200 mm Hg)在保护性通气策略基础上使用神经肌肉阻滞剂,ICU死亡率RR 0.73(95%CI 0.58–0.93,P=0.009)。
- 同一人群21–28天死亡率RR 0.63(95%CI 0.49–0.82,P=0.001),4项试验共527例。
- 48小时氧合改善WMD 27.98(95%CI 7.45–48.51,P=0.008),4项试验共212例。
- 24小时氧合(WMD 26.83,95%CI -5.89至59.55,P=0.108)及48小时平台压(WMD 0.43,95%CI -0.46至1.31,P=0.345)、呼气末正压(WMD 0.10,95%CI -0.47至0.67,P=0.73)无显著差异。
适用人群与场景
- 成人ARDS患者,氧合指数(动脉血氧分压/吸入氧浓度)≤200 mm Hg,符合美欧共识会议或柏林定义氧合标准。
- 所有纳入试验均基于保护性通气策略。
诊断标准与关键阈值
- ARDS氧合标准:氧合指数≤200 mm Hg,符合美欧共识会议或柏林定义。
研究设计与关键结果
- 研究类型:随机对照试验的荟萃分析,纳入5项试验共551例患者。
- ICU死亡率:神经肌肉阻滞剂组较安慰剂或常规治疗组降低,RR 0.73(95%CI 0.58–0.93,P=0.009,I²=0.0%,4项试验455例)。
- 21–28天死亡率:神经肌肉阻滞剂组较对照组降低,RR 0.63(95%CI 0.49–0.82,P=0.001,I²=0.0%,4项试验527例)。
- 48小时氧合:神经肌肉阻滞剂组改善,WMD 27.98(95%CI 7.45–48.51,P=0.008,I²=44.2%,4项试验212例)。
- 24小时氧合:无显著差异,WMD 26.83(95%CI -5.89至59.55,P=0.108,I²=82.4%,4项试验447例)。
- 48小时平台压:无显著差异,WMD 0.43(95%CI -0.46至1.31,P=0.345,4项试验455例)。
- 48小时呼气末正压:无显著差异,WMD 0.10(95%CI -0.47至0.67,P=0.73,4项试验455例)。
证据类型、等级与局限
- 证据类型:系统评价与荟萃分析,证据等级III级。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于氧合指数≤200 mm Hg的成人ARDS患者,在保护性通气策略基础上使用神经肌肉阻滞剂可降低ICU死亡率和21–28天死亡率;该结论来自5项随机对照试验的荟萃分析。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: To explore the effect of neuromuscular blocking agents (NMBAs) on adult patients with acute respiratory distress syndrome (ARDS) by meta-analysis.
METHODS: Three databases including Cochrane central register of controlled trials, PubMed, and Wanfang Data were searched to find relevant articles. We included randomized controlled trials that evaluated NMBAs compared with placebo or usual treatment in adult patients with ARDS.
RESULTS: Five trials totaling 551 patients were identified eligible for inclusion. All the five trials were protective ventilation strategies based. All patients (the ratio of partial pressure of arterial oxygen/fraction of inspired oxygen ≤ 200 mm Hg) met American-European Consensus Conference or the Berlin definition oxygenation criteria for ARDS. Neuromuscular blocking agents significantly reduced intensive care unit mortality (relative risk, 0.73; 95% confidence intervals [CI], 0.58-0.93; p = 0.009; I = 0.0%; 4 trials, 455 patients) and 21- to 28-day mortality (relative risk, 0.63; 95% CI, 0.49-0.82; p = 0.001; I = 0.0%; 4 trials, 527 patients). At 48 hours, NMBAs improved oxygenation (weighted mean differences [WMD], 27.98; 95% CI, 7.45-48.51; p = 0.008; I = 44.2%; 4 trials, 212 patients). However, NMBAs have no effect on reduction of oxygenation at 24 hours (WMD, 26.83; 95% CI, -5.89 to 59.55; p = 0.108; I = 82.4%; 4 trials, 447 patients), and plateau pressure (WMD, 0.43; 95% CI, -0.46 to 1.31; p = 0.345; 4 trials, 455 patients) as well as positive end expiratory pressure (WMD, 0.10; 95% CI, -0.47 to 0.67; p = 0.73; 4 trials, 455 patients) at 48 hours.
CONCLUSION: Protective ventilation strategies based NMBAs treatment reduces mortality in patients with moderate to severe ARDS.
LEVEL OF EVIDENCE: Systematic reviews & meta-analysis, level III.
参考来源
- Tao W, Yang LQ, Gao J, et al. Neuromuscular blocking agents for adult patients with acute respiratory distress syndrome: A meta-analysis of randomized controlled trials. J Trauma Acute Care Surg. 2018. PMID: 30462621. doi:10.1097/TA.0000000000002057
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。